Distinct computed tomography features of non-small-cell lung cancer in a European population with EML4-ALK translocation
2017
Background
Treatment of advanced EML4-ALK-translocation-positive non-small-cell lung cancer (NSCLC) with an ALK tyrosine kinase inhibitor (TKI) is now standard of care. Since EML4-ALK gene fusion is rare in NSCLC and testing depletes both tissue samples and health care funds, deciding who to screen is critical. CT features associated with EML4-ALK-positive cases may help prioritize individual patients for ALK testing in settings where biopsy size or health care factors make ubiquitous testing difficult.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
35
References
1
Citations
NaN
KQI